TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Universal PropTech Inc. ("UPI" or the "Company", TSXV: UPI.H) announces that the common shares of the Company are expected to be voluntarily delisted...
- Strong Macroplastique(R) Year-over-Year U.S. Sales Growth - - Significant Publication & Presentation Schedule for Uroplasty Products - - Conference Call to be Held Today at 3:30 pm Central Time...
MINNEAPOLIS, Jan. 20 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI) announced today that it will release financial results for the third fiscal quarter ended December 31, 2009, at...
Significant symptom improvement from Uroplasty's Urgent(R) PC treatments previously demonstrated at 12 weeks continued at 12 months MINNEAPOLIS, Dec. 10 /PRNewswire-FirstCall/ -- Uroplasty, Inc...
MINNEAPOLIS, Nov. 17 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of...
- Macroplastique(R) Year-over-Year U.S. Sales Continue Strong Growth - - SUmiT Trial Results Recommended for Publication in Journal of Urology - - Conference Call to be Held Today at 3:30 pm...
80% of Patients Treated with Urgent PC Reported Improvement Compared to 55% of Those Using an OAB Drug in a Study Published in September's Journal of Urology MINNEAPOLIS, Sept. 3...
- Macroplastique(R) year-over-year U.S. Sales Double - - SUmiT Trial Nears Completion - - Conference Call to be Held Today at 3:30 pm Central Time - MINNEAPOLIS, Aug. 3 /PRNewswire-FirstCall/...
MINNEAPOLIS, July 27 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (AMEX:UPI) announced today that it will release financial results for the first fiscal quarter ended June 30, 2009, at the market...
MINNEAPOLIS, July 13 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.03 | 0.03 | 0.03 | 0 | 0 | CS |
4 | 0 | 0 | 0.03 | 0.03 | 0.03 | 0 | 0 | CS |
12 | 0 | 0 | 0.03 | 0.03 | 0.03 | 0 | 0 | CS |
26 | 0 | 0 | 0.03 | 0.03 | 0.03 | 0 | 0 | CS |
52 | 0 | 0 | 0.03 | 0.03 | 0.03 | 0 | 0 | CS |
156 | -0.13 | -81.25 | 0.16 | 0.19 | 0.03 | 35587 | 0.07894696 | CS |
260 | -0.19 | -86.3636363636 | 0.22 | 0.75 | 0.03 | 90724 | 0.26865709 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales